Clinical trialNCT01002248TerminatedPhase 3Interventional

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

SponsorAEterna ZentarisEnrollment135Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Paul Richardson, MD
Dana-Farber Cancer Institute
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

86 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Facility name not stated
Winnipeg, Manitoba, Canada
Facility name not stated
Montreal, Quebec, Canada
Facility name not stated
Montreal, Quebec, Canada
Facility name not stated
Québec, Quebec, Canada

Czechia

Facility name not stated
Brno, Czech Republic, Czechia
Facility name not stated
Prague, Czech Republic, Czechia

Ireland

Keryx / Aoi Pharmaceuticals Investigative Site
Dublin, Ireland
Facility name not stated
Dublin, Ireland
Facility name not stated
Galway, Ireland
Facility name not stated
Limerick, Ireland
Facility name not stated
Sligo, Ireland
Facility name not stated
Tullamore, Ireland
Facility name not stated
Waterford, Ireland

Israel

Facility name not stated
Afula, Israel
Facility name not stated
Ashkelon, Israel
Facility name not stated
Beersheba, Israel
Facility name not stated
Haifa, Israel
Facility name not stated
Jerusalem, Israel
Facility name not stated
Jerusalem, Israel
Facility name not stated
Nahariya, Israel
Facility name not stated
Petah Tikva, Israel
Facility name not stated
Rehovot, Israel
Facility name not stated
Tel Aviv, Israel
Facility name not stated
Tel Litwinsky, Israel

Russia

Facility name not stated
Moscow, Russia
Facility name not stated
Moscow, Russia
Facility name not stated
Saint Petersburg, Russia
Facility name not stated
Saint Petersburg, Russia
Facility name not stated
Samara, Russia

Slovakia

Facility name not stated
Košice, Slovak Republic, Slovakia

South Korea

Facility name not stated
Seoul, South Korea
Facility name not stated
Seoul, South Korea
Facility name not stated
Seoul, South Korea
Facility name not stated
Seoul, South Korea
Facility name not stated
Seoul, South Korea

Spain

Facility name not stated
Badalona, Spain
Facility name not stated
Barcelona, Spain
Facility name not stated
Barcelona, Spain
Facility name not stated
Barcelona, Spain
Facility name not stated
Madrid, Spain

46 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bortezomib →Dexamethasone →Perifosine →Perifosine Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2009
Primary completion: 31 Mar 2013
Completion: 31 Mar 2013
Last update posted: 9 Feb 2018
Registered enrollment: 135
Registry id: NCT01002248

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.